摘要:
3-amino-3-arylpropan-1-ol compounds of formula I: R1 and R2 independently denoting C1-6 alkyl, or together denoting a (CH2)2-6 ring optionally substituted by phenyl, R3 denoting C3-6 alkyl, C3-6 cycloalkyl, aryl optionally containing heteroatoms and optionally substituted by R6 to R8, or a substituted C1-3 alkylphenyl of formula XII: R4 and R5 independently denoting C1-6 alkyl, C3-6 cycloalkyl, phenyl, benzyl, or phenethyl, or together forming a (CH2)3-6 or CH2CH2OCH2CH2 ring, R6 to R8 independently denoting H, F, Cl, Br, CHF2, CF3, OH, OCF3, OR14, NR15R16, SR14, phenyl, SO2CH3, SO2CF3, C1-6 alkyl, CN, COOR14, or CONR15R16, or together forming a OCH2O, OCH2CH2O, CH═CHO, CH═C(CH3)O or (CH2)4 ring, R14 denoting C1-6 alkyl, phenyl, benzyl, or phenethyl, R15 and R16 independently denoting H, C1-6 alkyl, phenyl, benzyl or phenethyl, and A denoting optionally substituted aryl optionally containing heteroatoms, or a diastereomer or enantiomer or pharmaceutically acceptable salt thereof, and their preparation and use in pharmaceutical compositions.
摘要:
3-amino-3-arylpropan-1-ol compounds corresponding to the formula I in which R1 to R5, A and X have the meanings according to claim 1, and their preparation and use as medicaments.
摘要:
Spirocyclic cyclohexane compounds corresponding to formula I a process for manufacturing such compounds, pharmaceutical compositions that contain such compounds, and the use of such spirocyclic cyclohexane compounds for the production of pharmaceuticals, and particularly for the treatment of pain.
摘要:
Substituted oxadiazole compounds corresponding to formula I: in which X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2; R1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R2 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; a C1-3 alkyl chain-attached aryl group, in each case unsubstituted or mono- or polysubstituted; and R3 and R4 independently denote H; C1-6 alkyl, in each case saturated or unsaturated, branched or unbranched, wherein R3 and R4 do not simultaneously mean H; or R3 and R4 together denote CH2CH2OCH2CH2, or (CH2)3-6. The compounds have an affinity for the μ-opioid receptor and may take the form of the racemate; enantiomers, diastereomers, mixtures of enantiomers or diastereomers, an individual enantiomer or diastereomer, a free base, or a salt with a physiologically acceptable acid.
摘要翻译:对应于式I的取代的恶二唑化合物:其中X表示CH,CH 2,CH-CH,CH 2 CH 2,CH 2 CH-CH或CH 2 CH 2 CH 2; R 1表示芳基或杂芳基,在每种情况下是未取代的或单取代或多取代的; 或者C 1-3烷基连接的芳基或杂芳基,在各种情况下是未取代的或单取代或多取代的; R 2表示芳基或杂芳基,在各种情况下为未取代或单取代或多取代; 在各种情况下为未取代或单取代或多取代的C 1-3烷基链连接的芳基; R3和R4独立地表示H; C 1-6烷基,各自为饱和或不饱和的,支链或非支链的,其中R3和R4不同时表示H; 或者R 3和R 4一起表示CH 2 CH 2 OCH 2 CH 2或(CH 2)3-6。 这些化合物对μ-阿片受体具有亲和力,并且可以采取外消旋体的形式; 对映体,非对映异构体,对映异构体或非对映异构体的混合物,单独的对映异构体或非对映体,游离碱或与生理上可接受的酸的盐。
摘要:
Substituted imidazoline derivatives corresponding to Formula I: a method for producing them from substituted aldehyde compounds of Formula B: and the use of such imidazoline derivatives and aldehyde compounds to treat pain, depression, urinary incontinence, diarrhea, pruritus, alcohol and drug misuse, drug dependency, lethargy and/or anxiety.
摘要:
Substituted oxadiazole compounds corresponding to formula I: in which X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2; R1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R2 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; a C1-3 alkyl chain-attached aryl group, in each case unsubstituted or mono- or polysubstituted; and R3 and R4 independently denote H; C1-6 alkyl, in each case saturated or unsaturated, branched or unbranched, wherein R3 and R4 do not simultaneously mean H; or R3 and R4 together denote CH2CH2OCH2CH2, or (CH2)3-6. The compounds have an affinity for the μ-opioid receptor and may take the form of the racemate; enantiomers, diastereomers, mixtures of enantiomers or diastereomers, an individual enantiomer or diastereomer, a free base, or a salt with a physiologically acceptable acid.
摘要翻译:对应于式I的取代的恶二唑化合物:其中X表示CH,CH 2,CH-CH,CH 2 CH 2,CH 2 CH-CH或CH 2 CH 2 CH 2; R 1表示芳基或杂芳基,在每种情况下是未取代的或单取代或多取代的; 或者C 1-3烷基连接的芳基或杂芳基,在各种情况下是未取代的或单取代或多取代的; R 2表示芳基或杂芳基,在各种情况下为未取代或单取代或多取代; 在各种情况下为未取代或单取代或多取代的C 1-3烷基链连接的芳基; R3和R4独立地表示H; C 1-6烷基,各自为饱和或不饱和的,支链或非支链的,其中R3和R4不同时表示H; 或者R 3和R 4一起表示CH 2 CH 2 OCH 2 CH 2或(CH 2)3-6。 这些化合物对μ-阿片受体具有亲和力,并且可以采取外消旋体的形式; 对映体,非对映异构体,对映异构体或非对映异构体的混合物,单独的对映异构体或非对映体,游离碱或与生理上可接受的酸的盐。
摘要:
Novel C-imidazo[1,2-α]pyridin-3-yl-methylamine compounds corresponding to formula I, wherein R1-R6 have the meanings provided in the description. Pharmaceutical compositions containing these compounds are also provided, as well as methods of using these compounds for treating or inhibiting various illnesses or other conditions.
摘要:
Novel 2-pyrrolidin-2-yl-1H-indole compounds corresponding to formula (I) wherein R1, R2, R3 and R4 have the meanings given in the description, and pharmaceutical compositions containing these compounds, as well as processes for the preparation of such compounds and intermediate products of this process, and related methods of treatment.
摘要翻译:对应于式(I)的新的2-吡咯烷-2-基-1H-吲哚化合物,其中R 1,R 2,R 3和R 3, R 4具有本说明书中给出的含义,含有这些化合物的药物组合物,以及该方法的这种化合物和中间产物的制备方法以及相关的治疗方法。
摘要:
Substituted 4-aminocyclohexanols, methods of producing the same, pharmaceuticals containing these compounds, the use of substituted 4-aminocyclohexanols for producing pharmaceutical compositions for the treatment of various indications, in particular pain, and for related treatment methods.
摘要:
The invention relates to substituted pyrido[1,2-a]pyrimidine compounds corresponding to formula (I) wherein: R1, R2 and R3 are as defined in the specification. Related pharmaceutical formulations and methods for inhibiting nitrogen oxide synthesis (NOS) and other treatments are also provided.